Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med ; 31(Special Issue 2): 1126-1131, 2023 Oct.
Article in Russian | MEDLINE | ID: mdl-38069874

ABSTRACT

The lessons of COVID-19 have confirmed the effectiveness of measures aimed at strict self-isolation and quarantine. In the People's Republic of China, where any violation of the regime requirements was qualified as a criminal offense, the virus was neutralized when the pandemic was only gaining momentum in Europe and America. However, without proper organization of a restrictive regime, self-isolation can lead to negative consequences in terms of deterioration of health and standard of living. The pandemic has undoubtedly significantly complicated our lives, has taken millions of lives, caused disability, deterioration of material status, rupture of marital ties. One of the reasons for this development of events was the unsatisfactory organization of leisure during self-isolation. The inability to calmly wait out, endure COVID-associated adversities in most countries caused mass popular unrest, gave rise to panic moods. Only those who managed to curb the negative consequences and direct them in the right direction managed to come out of the pandemic with dignity. The authors have developed an organizational technology of the forced self-isolation regime based on the complex of measures and proposed this technology for introduction to daily life of the population during the period of restrictive regimes. The authors are sure that it is especially important to organize leisure and create the most comfortable conditions of the isolated living for the elderly, who are the most sensitive to changes in life stereotypes. The authors propose a set of measures to efficiently organize leisure during self-isolation with physical therapy, cognitive training, as well as measures to fit the body and develop psychological relief, making it possible to reverse the threat of the pandemic in higher health potential and better family relations.


Subject(s)
COVID-19 , Humans , Aged , COVID-19/epidemiology , COVID-19/prevention & control , SARS-CoV-2 , Quarantine/psychology , Europe
2.
Article in Russian | MEDLINE | ID: mdl-26356615

ABSTRACT

AIM: To compare clinical and morphological results of treatment of ischemic stroke in three groups of patients which differed by the forms and duration of an antioxidant therapy. MATERIAL AND METHODS: A randomized clinical trial was performed in 8 vascular centers of the Russian Federation in 2010-2014. It included 373 patients with ischemic stroke in the carotid territory. Patients were randomized into 3 groups to receive different regimens of antioxidant therapy as an adjunct to standard therapy: control group (ascorbic acid; 132 patients); cytoflavin (20 ml per day for 10 days; 133 patients); cytoflavin (the dose was decreased to 10 ml per day from 11th to 20th day) (108 patients). Patient's condition was assessed in 1, 10 and 21 day by a complex of clinical, laboratory and instrumental methods. RESULTS AND CONCLUSION: The analysis of CT in 1th and 21th day revealed a significant 1,5-1,7- fold decrease in the cerebral ischemic lesion in both groups treated with cytoflavin with no significant morphologic changes in the ascorbic acid group. The percentage of patients with ischemic lesion, increased during days 1-21, was 2-fold higher in the ascorbic acid group compared to cytoflavin groups. Morphologic changes were correlated with clinical variables and outcome. In patients with ≥14 points on NIH scale on admission, prolonged 20 day cytoflavin therapy was associated with a more prominent improvement of neurologic, functional and cognitive status compared to 10-day cytoflavin infusion. No differences in clinical variables were observed in patients with mild symptoms (<14 points on NIH scale on admission) receiving cytoflavin for 10 and 20 days.


Subject(s)
Antioxidants/therapeutic use , Ascorbic Acid/therapeutic use , Brain Infarction/drug therapy , Brain Infarction/pathology , Flavin Mononucleotide/therapeutic use , Inosine Diphosphate/therapeutic use , Niacinamide/therapeutic use , Succinates/therapeutic use , Adult , Aged , Aged, 80 and over , Antioxidants/administration & dosage , Ascorbic Acid/administration & dosage , Brain Infarction/diagnostic imaging , Drug Combinations , Energy Metabolism , Female , Flavin Mononucleotide/administration & dosage , Humans , Infusions, Intravenous , Inosine Diphosphate/administration & dosage , Male , Middle Aged , Niacinamide/administration & dosage , Russia , Succinates/administration & dosage , Tomography, X-Ray Computed , Treatment Outcome
3.
Antibiot Khimioter ; 60(1-2): 27-34, 2015.
Article in Russian | MEDLINE | ID: mdl-26168682

ABSTRACT

Two hundred twenty one patients aged 32-93 years with brain infarction, admitted to a Vascular Neurology Center in the first 3-48 hours (mean 6 hours) after the onset of the symptoms of stroke with computed tomography (CT) verified diagnosis were enrolled in the study. According to the timing of the CT-verification the patients were divided into 2 groups: "early" visualization (EV 50.2%) and "late" visualization (LV, 49.8%). In the EV group the lesion was visualized by CT on the admission (3-6 hours after the admission), in the LV group it was visualized only when CT was repeated 2-3 days after the admission. The patients in the LV group demonstrated increased severity of the underlying pathology, increased mortality and unfavourable functional outcomes correlating with the stroke lesion volume vs. the EV group. There was observed pathophysiological correlation of the blood enzymatic spectrum and acid-base balance parameters, explaining the late lesion visualization by delayed and more pronounced intracellular energy synthesis stabilization mechanisms failure in the aerobic and anaerobic glycolysis cycles.


Subject(s)
Stroke , Tomography, X-Ray Computed , Adult , Aged , Aged, 80 and over , Disease-Free Survival , Humans , Male , Middle Aged , Stroke/blood , Stroke/diagnostic imaging , Stroke/mortality , Stroke/physiopathology , Survival Rate , Time Factors
4.
Eksp Klin Farmakol ; 78(1): 21-6, 2015.
Article in Russian | MEDLINE | ID: mdl-25826870

ABSTRACT

The paper reviews the preliminary results of a multicenter randomized clinical research. The aim of the study was to determine the optimal duration of different types of energy-correction therapy. 99 case report forms of patients with cerebral infarction were reviewed with their prior envelope randomization into three groups. Patients in the first group (experimental group), consisting of 32 patients, as part of combined therapy received ascorbic acid (5% solution twice a day in a recommended dosage of 20 ml/day for 20 days); the second group (37 patients) received 10 ml of cytoflavin intravenously by drop infusion twice a day for 10 days; the third group received cytoflavin for 20 days (from day 1 to day 10 - 20 ml a day, from day 11 to day 20 - 10 ml a day). The average NIH scale score on admission was 14.9 ± 2.6. Prescription of cytoflavin came with average 1.7 - 1.8 time regression (p < 0.05) of the volumes of cerebral ischemia in the of cases of the 10- and 20-day courses of treatment, while there were no significant morphologic changes in the ascorbic acid group. These results correlated with the best dynamics and outcomes of the neurological and performance status of patients receiving cytoflavin. Despite the lack of significant general differences in the clinical and morphological data of the second and third groups, the patients with underlying grave medical condition in the 20-day cytoflavin group (with NIH score of 14-20 points on admission) tended to have improved neurologic status parameters in comparison with the experimental group and the 10-day cytoflavin group. These results attest to the advantages of personalized antioxidant energy-correction therapy.


Subject(s)
Antioxidants/therapeutic use , Ascorbic Acid/therapeutic use , Cerebral Infarction/drug therapy , Flavin Mononucleotide/therapeutic use , Inosine Diphosphate/therapeutic use , Niacinamide/therapeutic use , Succinates/therapeutic use , Aged , Cerebral Infarction/pathology , Cerebral Infarction/physiopathology , Cognition/drug effects , Drug Administration Schedule , Drug Combinations , Female , Humans , Male , Middle Aged , Precision Medicine , Psychological Tests , Russia , Severity of Illness Index , Treatment Outcome
5.
Article in Russian | MEDLINE | ID: mdl-25591516

ABSTRACT

OBJECTIVE: To determine the optimal duration of energy corrective treatment of ischemic stroke (II) with cytoflavin or ascorbic acid. MATERIAL AND METHODS: A multicenter randomized clinical trial included 185 patients, aged 40-75 years. Patients were randomized into 3 groups: the control group (n=64) received ascorbic acid; cytoflavin group 1 (n=72) was treated for 10 days and cytoflavin group 2 (n=49) for 20 days. In all groups, mean NIHSS score was 13, 42.2% of patients scored ≥14 and on admission, 42.2% of patients had consciousness impairment of different severity. RESULTS: Cytoflavin treatment was more efficient than ascorbic acid that can be explained by different pharmacologic mechanisms. Treatment with cytoflavin for 10 days resulted in a significant decrease of ischemia zone volume by 25.2%, treatment with cytoflavin for 20 days - by 29.0%, which was associated with better outcomes in neurologic and functional status. Ascorbic acid demonstrated no effect on morphologic parameters. Prolonged treatment with cytoflavin in critically ill patients led to significant improvement in clinical and morphologic variables compared to the 10-day course. In patients with less severe condition comparable results were obtained. CONCLUSION: Our data justify the need for personalized integrated antioxidant and energy correction therapy.


Subject(s)
Antioxidants/therapeutic use , Ascorbic Acid/therapeutic use , Brain Infarction/drug therapy , Brain Ischemia/drug therapy , Flavin Mononucleotide/therapeutic use , Inosine Diphosphate/therapeutic use , Niacinamide/therapeutic use , Succinates/therapeutic use , Adult , Aged , Antioxidants/adverse effects , Ascorbic Acid/adverse effects , Drug Combinations , Female , Flavin Mononucleotide/adverse effects , Humans , Inosine Diphosphate/adverse effects , Male , Middle Aged , Niacinamide/adverse effects , Succinates/adverse effects , Treatment Outcome
6.
Adv Gerontol ; 27(4): 746-52, 2014.
Article in Russian | MEDLINE | ID: mdl-25946854

ABSTRACT

In the multicenter randomized clinical-instrumental prospective study 185 patients aged 55-75 years (mean age 68 years) with 94 men and 91 women with cerebral infarction were included. All the patients were hospitalized in the period from 6 to 24 hours from the time of the debut of clinical symptoms, 42,2% of patients scored 14 and above on NIH scale on admission. Patients were randomized into 3 groups: 1st group consisted of 64 patients treated as an antioxidant by 5% solution of ascorbic acid 2 times a day the recommended dose (20 ml/day) for 20 days; 2nd group consisted of 72 patients who received energy monitor Cytoflavin in a daily dose of 20 ml (10.0 ml/drip 2 times a day for 10 days); 3rd group consisted of 49 patients with Cytoflavin therapy extended to 20 days, moreover from 11th to 20th day the dose was 10 ml/day. Cytoflavin treatment was more efficient than ascorbic acid, which can be explained by different pharmacologic mechanisms. Treatment with Cytoflavin for 10 days resulted in a significant decrease of ischemia zone volume by 25% in average, treatment with Cytoflavin for 20 days--by 29%, which manifested in better outcomes in neurologic and functional status. Ascorbic acid demonstrated no effect on morphologic parameters. Patients having at the time of admission 18-20 points according to the NIH and treated with Cytoflavin for 20 days demonstrated significant trend towards improvement of the parameters of the neurological status.


Subject(s)
Antioxidants/therapeutic use , Ascorbic Acid/therapeutic use , Energy Metabolism/drug effects , Flavin Mononucleotide/therapeutic use , Homeostasis/drug effects , Inosine Diphosphate/therapeutic use , Niacinamide/therapeutic use , Stroke/drug therapy , Succinates/therapeutic use , Aged , Aged, 80 and over , Ascorbic Acid/administration & dosage , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Combinations , Female , Flavin Mononucleotide/administration & dosage , Humans , Inosine Diphosphate/administration & dosage , Male , Middle Aged , Niacinamide/administration & dosage , Prospective Studies , Severity of Illness Index , Stroke/metabolism , Succinates/administration & dosage , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...